US Patent 7,807,708 Landscape: Ligand Compound (Formula I) Covering Broad Substitution Space Plus Cosmetic/Pharma Compositions
US 7,807,708 claims a chemical “ligand compound” defined by a very broad Markush-style core structure (Formula (I)) with wide latitude on substituents (R1-R7, Y, Ar, X, A, n) and then scales the coverage into specific compound exemplars and into product formulations (cosmetic and pharmaceutical). The claim set is structured to provide (1) broad structural capture of the underlying scaffold, (2) multiple fallback restrictions (subsets of Ar, Y, and ring-closure cases), and (3) composition claims with formulation ranges.
What exactly is claimed in US 7,807,708?
Core product of the claims: “ligand compound” of Formula (I)
Claim 1 is the main coverage engine. It defines a ligand compound “having the formula (I) below” with the following substituent logic (verbatim claim logic, normalized into a scope map).
Variable groups in Formula (I) (Claim 1)
- R1: hydrogen; alkyl C1 to C4; or CF3
- R2: hydrogen; alkyl or alkoxy C1 to C4; or chlorine
- R3: hydrogen; linear or branched alkyl or alkoxy C1 to C10, optionally substituted with methoxy
- R4: hydrogen or alkyl C1 to C3
- R5: hydrogen or alkyl C1 to C3
- or R4 and R5 together form, with the bond “—N—C(=Y)—”, a ring: pyrrolidine, pyrrolrolidinone, piperidine, or piperidinone
- Y: two hydrogens or a hetero atom
- Ar (aromatic ring options): 1,4-phenyl; 2,5-pyridyl; 5,2-pyridyl; 2,5-thiophenyl
- X: oxygen (optionally substituted with alkyl or alkylamine) or a C-C single bond
- A: hydrogen or a specified additional substituent fragment (claim depicts a further moiety parameterized by Q, R6)
- Q: oxygen or “—NH—”
- R6: hydrogen; alkyl C1 to C6; cycloalkyl C3 to C6; or acyl fragments —C(O)CH3 or —C(O)CH2CH3
- R7 and R7’: independently H or hydroxyl, with the limitation they are not both hydroxyl
- n: 0 to 5
- Salts: includes salts when R3 is hydrogen and includes geometrical isomers
What this structure means commercially: Claim 1 captures not one compound, but a family defined by a complex scaffold with controlled ring-closure options (R4/R5) and broad freedom in peripheral groups.
Factual narrowing via dependent claims (subset capture)
The following dependent claims tighten Formula (I) to specific parameter selections:
- Claim 2: R1 is —CF3
- Claims 3-6: restrict Ar to one of the listed rings
- Claim 3: 1,4-phenyl
- Claim 4: 2,5-pyridyl
- Claim 5: 5,2-pyridyl
- Claim 6: 2,5-thiophenyl
- Claims 7-8: restrict Y
- Claim 7: Y = oxygen
- Claim 8: Y = sulfur
- Claim 9: specifies the ring closure case where R4 and R5 together form one of the listed N-containing rings
- Claim 10: salt types (alkali/alkaline earth, zinc, or organic amine salt / acid addition partner when basic)
- Claims 11-16: constrain carbon count variants within alkyl groups
- Claim 11: alkyl C1 to C3 = methyl/ethyl/i-propyl/n-propyl
- Claim 12: alkyl C1 to C4 = methyl/ethyl/i-propyl/i-butyl/t-butyl
- Claim 13: alkyl C1 to C10 = expanded list including pentyl through dodecyl
- Claim 14: alkoxy C1 to C10 = methoxy/ethoxy/isopropyloxy/tert-butyloxy/hexyloxy
- Claim 15: alkoxy C1 to C4 = methoxy/ethoxy/isopropyloxy/tert-butyloxy
- Claim 16: cycloalkyl C3 to C6 = cyclopropyl/cyclopentyl/cyclohexyl
- Claim 17: lists a large group of specific named/numbered ligand compounds (the most concrete embodiment set)
- Claims 18-19: add “all of the following conditions” limitation subsets (a structured fallback)
- Claim 18:
- R1 is H or t-butyl or i-propyl
- R2 is H or t-butyl or i-propyl
- R3 is H or ethyl
- R4 and R5 are independently methyl/ethyl or together form pyrrolidine ring
- A as defined with R6 in a smaller set (H, i-propyl/t-butyl, cycloalkyl C3 to C6, or acetyl fragments)
- Claim 19: Claim 18 conditions plus explicit “all of the following conditions” framing (same parameter list)
Product-formulation claims: cosmetic and pharmaceutical
Claims move from molecule to compositions:
- Claim 20: a cosmetic composition comprising a cosmetically effective amount of at least one ligand compound of Claim 1 in a cosmetically and physiologically acceptable medium
- Claim 21: ligand compound concentration 0.001% to 3% by weight
- Claim 22: cosmetic composition formulated for body or hair hygiene
- Claim 25: cosmetic composition for preventing and/or treating signs of aging and/or dry sun
- Claim 23: a pharmaceutical composition comprising a pharmaceutically effective amount of at least one ligand compound of Claim 1 in a pharmaceutically and physiologically acceptable medium
- Claim 24: ligand compound concentration 0.0001% to 10% by weight
Specific “claim 27” singled out
- Claim 27: the ligand compound is specifically
3″-tert-butyl-4′-(2-hydroxyethoxy)-4″-pyrrolidin-1-yl[1,1′;3′,1″]terphenyl-4-carboxylic acid
That is a final, high-precision fallback to an individual marketed-like candidate in the compound list.
How broad is Claim 1 in practical infringement terms?
Breadth drivers
Claim 1’s breadth comes from three structural “degrees of freedom” that can map to many potential design-arounds:
-
Peripheral substituent latitude
- R1-R3 allow a wide selection (including C1-C10 alkoxy/alkyl and optional methoxy substitution on R3).
- R2 includes halogen (chlorine) in addition to alkyl/alkoxy.
-
Ring-closure option
- R4 and R5 can be independent small alkyls, or they can cyclize into a nitrogen-containing ring system (pyrrolidine/pyrrolidinone/piperidine/piperidinone).
This creates a larger “claim canvas” than a single fixed ring topology.
-
Ar and Y/X toggles
- Ar is one of four aromatic systems, including two positional pyridyl isomers and a thiophene ring.
- Y can be hetero (including explicit dependent claims for oxygen and sulfur), and X can be oxygen (with substitution) or a C-C single bond.
Compression effects (what narrows capture)
Even with broad options, the scope is constrained by:
- A defined scaffold topology: the “formula (I) below” anchors all variations to a single structural template.
- Variable group A has fixed sub-structure logic (Q is oxygen or —NH—; R6 belongs to a constrained list of sizes/types).
- R7/R7’ cannot both be hydroxyl.
Net effect: the claim is “wide within a scaffold,” then “narrow by exact scaffold match.”
What do the dependent claims do for claim strength and design-around strategy?
Subset claims provide litigation fallback positions
The dependent claims create a ladder:
- Start with Claim 1 (maximal Markush scope)
- Narrow via Ar (Claims 3-6), Y (Claims 7-8), and R1 (Claim 2)
- Narrow further via ring-closure (Claim 9), specific alkyl/alkoxy/cycloalkyl sets (Claims 11-16)
- Then narrow to “scenario” subsets (Claims 18-19)
- Then lock to specific exemplars (Claim 17) and a single compound (Claim 27)
- Finally move to formulation (Claims 20-25; concentration ranges)
Design-around surfaces created by the claim grammar
A challenger typically attacks scope at the “variable definition” level, but here those are too many to enumerate as a single bypass. The most practical bypass attempts are to:
- change the Ar set,
- change the Y/X functionality outside the allowed categories,
- avoid the specific scaffold mapping that allows the ring closure combination and A fragment alignment,
- or, for product infringement, ensure the formulation does not contain a captured “ligand compound.”
The presence of both molecule and formulation claims means even if a party avoids one exemplar, the molecule-claim family could still ensnare alternate members.
What is the claimed compound set in Claim 17 (exemplar coverage)?
Claim 17 enumerates a large group of specific ligand compounds by explicit chemical names/structures. The list in the user-provided claim text includes at least:
- Ethyl esters and carboxylic acids with terphenyl scaffolds
- Variants with:
- hydroxybutoxy, hydroxyethoxy, hydroxypropoxy
- pyrrolidinyl substitution (including N-acyl/oxo variants such as 2-oxopyrrolidin-1-yl and 2-oxopiperid-1-yl patterns)
- diethylamino or ethylamino substituents
- trifluoromethyl substituent cases
- multiple substitution patterns on the terphenyl/biphenyl system (including nicotinic acid/pyridine-2-carboxylic acid/thiophene carboxylic acid analogs in the later portion of the list)
Two value points for business analysis:
- Claim 17’s exemplars are not just “covering named products.” They show that the patent is written for a catalog of analogs, likely aligned to series synthesis.
- Claim 27 indicates at least one exemplar is treated as a standalone fallback.
What is the patent landscape around US 7,807,708?
Landscape classification by claim purpose
US 7,807,708 is best characterized as:
- Chemistry scaffold patent with broad Markush coverage (Claim 1, 17, 27)
- Application extension into:
- cosmetic compositions (Claims 20-22, 25)
- pharmaceutical compositions (Claims 23-24)
This type of patent typically creates a “series lock” across multiple analogs and multiple use-form factors.
What the provided record supports (and what it does not)
Your prompt provides the claim set text but does not include:
- filing date / priority date
- assignee/applicant
- prosecution history
- related family members
- cited documents or forward citations
- expiration, terminal disclaimers, or patent term adjustments
Because those data are necessary to place the patent precisely in a family/expiry map and to quantify overlaps with specific competitors, the landscape below is restricted to what can be derived strictly from the provided claim content.
Freedom-to-operate implications derived from the claim set
FTO risk categories
A product or candidate falls into different risk buckets depending on infringement theory:
-
Direct product risk (molecule capture)
- If the candidate ligand matches Formula (I) with the allowed ranges of R1-R7, Y, Ar, X, A, and n, then it can fall under Claim 1 regardless of whether it matches one listed exemplar in Claim 17.
-
Direct product risk (exemplar capture)
- If the candidate is one of the enumerated compounds in Claim 17 or the single compound in Claim 27, then direct capture is much more likely on claim construction.
-
Formulation risk (cosmetic/pharma composition)
- Even if a product avoids one molecule, the composition claims can still apply if it contains “at least one” captured ligand compound.
- The presence of wide concentration ranges (0.001%-3% for cosmetic; 0.0001%-10% for pharma) reduces the ability to “escape” by formulation strength if the active is within Claim 1.
Where design effort most often targets in this type of claim
- Switch the aromatic core away from the allowed Ar set (1,4-phenyl; 2,5-/5,2-pyridyl; 2,5-thiophenyl).
- Change Y away from the allowed hetero logic (with the additional narrowing that Claim 7 and 8 explicitly cover oxygen/sulfur).
- Alter the X linkage away from oxygen or the allowed substituted oxygen behavior or the C-C single bond situation.
- Adjust A fragment logic (Q and R6 class).
- Avoid ring closure that relies on R4/R5 forming one of the N-ring systems under the specified -N-C(=Y)- relationship.
Key Takeaways
- Claim 1 is a broad scaffold family built from a Markush Formula (I) with wide latitude on R1-R3, Ar, Y, X, and A, plus optional ring-closure from R4/R5.
- Dependent claims create multiple fallback footholds covering specific high-value subsets: CF3 (Claim 2), each Ar variant (Claims 3-6), oxygen/sulfur Y (Claims 7-8), ring closure (Claim 9), and specific alkyl/alkoxy/cycloalkyl lists (Claims 11-16).
- Claim 17 is an exemplar roster listing dozens of concrete ligand compounds, indicating series coverage, not a single lead.
- Product claims extend the scope into use/formulation with specific concentration windows for cosmetic (0.001%-3% by weight; body/hair hygiene; aging/dry sun) and pharma (0.0001%-10% by weight).
- Claim 27 anchors a single standout compound as a dedicated fallback position.
FAQs
1. Does US 7,807,708 protect only one compound?
No. Claim 1 protects a family of ligand compounds defined by Formula (I) with broad parameter ranges, with additional coverage for specific exemplars in Claim 17 and a single compound in Claim 27.
2. Are salts and geometrical isomers included?
Yes. Claim 1 explicitly includes salts when R3 is hydrogen and includes geometrical isomers of Formula (I).
3. Can a cosmetic product be infringing even if it is not one of the listed examples?
Yes. Claims 20-22 and 25 cover cosmetic compositions containing “at least one” ligand compound defined by Claim 1, not only the enumerated exemplars.
4. What concentration ranges are claimed for cosmetic and pharmaceutical compositions?
Cosmetic: 0.001% to 3% by weight (Claim 21). Pharmaceutical: 0.0001% to 10% by weight (Claim 24).
5. What are the most important narrowing parameters besides the scaffold?
The most prominent narrowing parameters in the dependent set are R1 (including CF3), Ar, Y (oxygen or sulfur), ring closure via R4/R5, and specific allowed sets for alkyl/alkoxy/cycloalkyl groups.
References
[1] US Patent 7,807,708 (claims as provided in user prompt).
